Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials

Table 4 Top 8 system adverse reactions in RCTs

SOC	David A. Reardon (all)		Chiara Cremolini (> third grade)		Ingrid U Scott		Cesare Gridelli		Hiroaki Akamatsu		Marla Lipsyc-Sharf		Sermsiri Sangroongruangsri		Matthew H Kulke		Summary
SOC	Bev	Non-Bev	Bev	Non-Bev	Bev	Non-Bev	Bev	Non-Bev	Bev	Non-Bev	Bev	Non-Bev	Bev	Non-Bev	Bev	Non-Bev
Vascular disorders	37	1	2	1	0	1	54	28	2	0	17	14	250	3	29	6	445
Investigations	2	20							142	134	14	12			1	0	325
General disorders and administration site conditions	23	38	5	6			79	62	10	10	0	1			8	6	248
Metabolism and nutritional disorders	0	2					28	20	55	65	17	14			22	12	235
Blood and lymphatic system disorders			20	19			74	70	13	27			13	11	12	7	226
Gastrointestinal disorders	11	7	13	18			35	34	19	20	19	18	6	0	10	3	213
Skin and subcutaneous tissue	6	23	7	11			17		15	14	31	30					154
Respiratory, thoracic and mediastinal disorders	6	4					38	49	11	10			1	0			119

ISSN: 2055-0294